ANIP Ani Pharmaceuticals Inc

Price (delayed)

$34.87

Market cap

$601.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.68

Enterprise value

$806.64M

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
ANIP's quick ratio has surged by 82% year-on-year
Ani Pharmaceuticals's revenue has increased by 6% YoY and by 4.6% from the previous quarter
The company's equity has surged by 58% YoY but it fell by 3.8% QoQ
The debt has soared by 57% YoY
Ani Pharmaceuticals's net income has decreased by 47% QoQ

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
17.25M
Market cap
$601.4M
Enterprise value
$806.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
2.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
Earnings
Revenue
$226.09M
EBIT
-$65.95M
EBITDA
-$15.04M
Free cash flow
-$37.45M
Per share
EPS
-$4.68
Free cash flow per share
-$2.32
Book value per share
$18.6
Revenue per share
$14.01
TBVPS
$26.96
Balance sheet
Total assets
$744.85M
Total liabilities
$398.75M
Debt
$287.16M
Equity
$321.24M
Working capital
$221.87M
Liquidity
Debt to equity
0.89
Current ratio
3.79
Quick ratio
2.68
Net debt/EBITDA
-13.65
Margins
EBITDA margin
-6.7%
Gross margin
49.2%
Net margin
-27.8%
Operating margin
-28.6%
Efficiency
Return on assets
-10.3%
Return on equity
-24.4%
Return on invested capital
-14%
Return on capital employed
-9.9%
Return on sales
-29.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
0.72%
1 week
3.26%
1 month
10.87%
1 year
5.47%
YTD
-24.33%
QTD
17.53%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$226.09M
Gross profit
$111.2M
Operating income
-$64.7M
Net income
-$62.82M
Gross margin
49.2%
Net margin
-27.8%
The company's operating income fell by 48% QoQ
Ani Pharmaceuticals's net income has decreased by 47% QoQ
ANIP's operating margin is down by 42% since the previous quarter
The net margin has decreased by 41% QoQ

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.87
P/S
2.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
The company's EPS fell by 38% QoQ
The company's equity has surged by 58% YoY but it fell by 3.8% QoQ
The P/B is 38% below the 5-year quarterly average of 3.0
The price to sales (P/S) is 19% higher than the last 4 quarters average of 2.1 but 17% lower than the 5-year quarterly average of 3.0
Ani Pharmaceuticals's revenue has increased by 6% YoY and by 4.6% from the previous quarter

Efficiency

How efficient is Ani Pharmaceuticals business performance
The company's return on sales fell by 43% QoQ
Ani Pharmaceuticals's ROIC has decreased by 32% from the previous quarter
The ROA has contracted by 32% from the previous quarter
The return on equity has declined by 31% since the previous quarter

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 87% more than its total liabilities
ANIP's quick ratio has surged by 82% year-on-year
The company's current ratio has surged by 71% YoY and by 3% QoQ
The debt is 11% lower than the equity
The company's equity has surged by 58% YoY but it fell by 3.8% QoQ
The debt has soared by 57% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.